Leading Players in India Rheumatoid Arthritis Market | Top Companies & Insights 2026

India Rheumatoid Arthritis Market Overview

According to 6Wresearch, the India rheumatoid arthritis market is projected to expand, fueled by a greater clinical emphasis on early intervention and the growing availability of advanced biologics and biosimilars. The industry distinguishes itself through a dual focus: maintaining a robust supply of affordable conventional DMARDs (Disease-Modifying Anti-Rheumatic Drugs) and pioneering high-quality biosimilar versions of blockbuster molecules like Infliximab and Adalimumab.

Competitive Landscape

The competitive landscape for rheumatoid arthritis in India is a strategic balance between global biopharmaceutical innovators and domestic leaders who have mastered the production of cost-effective biologics. Success in this market is dependent on achieving strict biosimilarity standards and maintaining high-fidelity cold chain distribution networks for injectable therapies.

Below is a list of leading players operating in the India Rheumatoid Arthritis Market:

1. Sun Pharmaceutical Industries Limited

India’s largest pharma firm; it leads the RA market with a diverse portfolio of NSAIDs and DMARDs, leveraging an extensive sales force to reach rheumatologists nationwide.

2. Cipla Limited

A leader in chronic care, Cipla provides high-access generic and biosimilar options, ensuring affordability for long-term autoimmune management.

3. Lupin Limited

Lupin holds a significant share with its immunology portfolio, focusing on cost-effective manufacturing of conventional tablets and specialized biologics.

4. Dr. Reddy’s Laboratories Ltd.

A global pioneer in biosimilars; it was among the first to launch rituximab and other critical biologics for RA in the Indian market.

5. Biocon Limited

India’s largest biopharmaceutical company, specializing in the development of complex biosimilars for inflammatory and autoimmune diseases.

6. Zydus Lifesciences Limited

Formerly Zydus Cadila, it is a major contributor to the RA pipeline, offering a wide range of anti-inflammatory medications and biosimilar injectables.

7. Ipca Laboratories Ltd.

A dominant player in the rheumatology segment, providing essential first-line treatments like hydroxychloroquine and leflunomide.

8. Torrent Pharmaceuticals Limited

Focuses on high-entry-barrier therapeutic segments, marketing trusted brands for chronic pain and joint inflammation.

9. Pfizer

Markets the innovative JAK inhibitor tofacitinib (Xeljanz), setting the benchmark for advanced oral therapies in refractory RA cases.

10. AbbVie Inc.

The global leader in immunology; its presence in India is defined by blockbuster molecules that have revolutionized the treatment of severe RA.

11. Novartis

Provides specialized biological therapies and has a strong focus on precision medicine and patient support programs in India.

12. Sanofi

A key player in the anti-inflammatory segment, Sanofi offers a range of corticosteroid and DMARD treatments for joint health.

13. Glenmark Pharmaceuticals Limited

Focuses on specialty generics and innovative oral medications for chronic inflammatory conditions.

14. Alembic Pharmaceuticals Limited

One of India’s oldest firms, providing stable and high-efficacy formulations for long-term arthritis care.

15. Alkem Laboratories Limited

Leverages a massive retail network to distribute affordable anti-arthritic tablets and pain management solutions across the subcontinent.